DOT1L and leukemia: GSEA analysis of the genesets of signatures of BRD4 (human homologues of Brd4 knockdown with p ≤ .01, unpaired t‐test and at least mean twofold decrease in expression),52 MENIN (CRISPR knockout with p ≤ .01, unpaired t‐test and at least mean twofold decrease in expression)53 and DOT1L inhibitor (EPZ004777 treatment of MOLM‐13 with p ≤ .01, unpaired t‐test and at least mean log twofold decrease in expression)17 all showed negative enrichment indicating that DSF interferes with these important signalling pathways in MLL‐rearranged leukaemias.